Futurity reported on research led by biomedical engineering Jonathan Lovell that found an experimental nanoparticle-based flu vaccine consisting of disease-fighting proteins was proven effective in preclinical studies. The technology could boost the effectiveness and accelerate the production of seasonal flu vaccines.
Medical Xpress and Science Magazine reported on research led by biomedical engineer Jonathan Lovell that found an experimental nanoparticle-based flu vaccine consisting of disease-fighting proteins was proven effective in preclinical studies.
Local news outlets including WKBW, WGRZ, The Lockport Journal and WIVB report that UB spinoff company POP Biotechnologies and biotech company EuBiologics have developed a COVID-19 vaccine candidate that has entered clinical trials in South Korea.
Business First reported that a COVID-19 vaccine developed by UB and Buffalo-based startup POP Biotechnologies has entered human clinical trials in South Korea.
